

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Virology

**Manuscript NO:** 66296

**Title:** Impact of Covid-19 on liver disease: from the experimental to the clinic perspective

**Reviewer's code:** 02522427

**Position:** Editorial Board

**Academic degree:** FACP, MBChB, MD

**Professional title:** Professor

**Reviewer's Country/Territory:** Saudi Arabia

**Author's Country/Territory:** Spain

**Manuscript submission date:** 2021-03-24

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-03-27 11:38

**Reviewer performed review:** 2021-04-01 09:01

**Review time:** 4 Days and 21 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

This is an interesting and very well written review on COVID19 impact on liver disease>  
I have to comments. For patients with chronic liver disease, it is better to discuss the difference between stable noncirrhotic patients or early cirrhotic patients (Child A low MELD score) compared to patients with advanced liver cirrhosis ( high Child and MED score) as patients with advanced disease are more prone to severe COVID19 consequences. Another important point that can be addressed is that many of those impact of COVID 19 on liver disease like delayed treatment and screening is related to budget and resources reallocation. This includes manpower and staff reallocation